

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT3738069

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
STEVEN JAMES MOSS	12/03/2015
MATTHEW ALAN GREGORY	12/03/2015
BARRIE WILKINSON	12/10/2015
STEVEN KENDREW	12/09/2015
RECEIVING PARTY DATA	
Name:	ISOMERASE
Street Address:	SUITE 9, SCIENCE VILLAGE
Internal Address:	CHESTERFORD RESEARCH PARK
City:	CAMBRIDGE
State/Country:	UNITED KINGDOM
Postal Code:	CB10 1XL
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	14903190
CORRESPONDENCE DATA	
Fax Number:	(215)563-4044
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(215) 563-4100
Email:	docketclerk@ddhs.com
Correspondent Name:	ROBERT C. NETTER, JR., PH.D., J.D.
Address Line 1:	1601 MARKET STREET
Address Line 2:	SUITE 2400
Address Line 4:	PHILADELPHIA, PENNSYLVANIA 19103
ATTORNEY DOCKET NUMBER:	5078-P06279US00
NAME OF SUBMITTER:	ROBERT C. NETTER, JR., PH.D., J.D.
SIGNATURE:	/Robert C. Netter, Jr./
DATE SIGNED:	02/12/2016
Total Attachments: 11	

source=ISO-P1742PCT IP102 Executed Assignment -SJM & MAG#page1.tif
source=ISO-P1742PCT IP102 Executed Assignment -SJM & MAG#page2.tif
source=ISO-P1742PCT IP102 Executed Assignment -SJM & MAG#page3.tif
source=ISO-P1742PCT IP102 Executed Assignment -SJM & MAG#page4.tif
source=ISO-P1742PCT IP102 Executed Assignment -BW#page1.tif
source=ISO-P1742PCT IP102 Executed Assignment -BW#page2.tif
source=ISO-P1742PCT IP102 Executed Assignment -BW#page3.tif
source=ISO-P1742PCT IP101 Executed Assignment SK#page1.tif
source=ISO-P1742PCT IP101 Executed Assignment SK#page2.tif
source=ISO-P1742PCT IP101 Executed Assignment SK#page3.tif
source=ISO-P1742PCT IP101 Executed Assignment SK#page4.tif

CONFIRMATORY ASSIGNMENT

WHEREAS WE **Steven James MOSS** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom, **Matthew Alan GREGORY** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom and **Barrie WILKINSON** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom (hereinafter called the "Inventors") have invented or discovered "**NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION**" (hereinafter called the "Invention") for which a PCT patent application was filed at the European Patent Office as Receiving Office under number PCT/GB2014/052094 on 9th July 2014 claiming priority to a patent application filed at the Intellectual Property Office in the United Kingdom under number 1312318.7 on 9th July 2013 (hereinafter called the "Applications");

WHEREAS **Steven James MOSS**, **Matthew Alan GREGORY** and **Barrie WILKINSON** were employed at the time of making of the Invention by **Isomerase Therapeutics Ltd.** whose registered address is Science Village, Chesterford Research Park, Cambridge CB10 1XL, United Kingdom (English company number 08335008, hereinafter called "ISOMERASE") and whereas the invention was made in the course of employment under circumstances whereby an invention may reasonably be expected to result and all rights in and to the invention are assigned to **ISOMERASE** by operation of law, specifically s39 of the Patents Act 1977, and moreover by virtue of a specific assignment clause in their contracts of employment;

WHEREAS the **Inventors** and **ISOMERASE** have authorised and requested the filing of the **Applications**;


NOW, THEREFORE, to all whom it may concern be it known that for consideration of the sum of £1 (one pound sterling) or other valuable consideration, the sufficiency of which is hereby acknowledged, we the **Inventors** hereby confirm the ownership by **ISOMERASE** of the **Invention** and the **Applications** and hereby assign and transfer to **ISOMERASE** all ownership right, title and interest in and to the **Invention** and the **Applications** and to any priority rights for all territories of the world in respect of the **Invention** and the **Applications** and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension, or re-issue thereof, or Supplementary Protection Certificate based

thereon, and we the Inventors hereby authorise and request any patent arising therefrom in any territory of the world be issued to **ISOMERASE**;

AND we the Inventors for ourselves and our respective executors and legal representatives hereby agree to provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **ISOMERASE** its successors and assigns, the whole right, title and interest in and to the **Invention** and the **Applications**.

IN WITNESS whereof and with effect from 9th July 2013 the **Inventors** and **ISOMERASE** through its authorised official have hereunto set their respective hands:


SIGNED by Steven James **MOSS**



.....

Date 3rd December 2015


in the presence of:



.....

NIGEL CORTES
30 PPRAY WALK
CAMBRIDGE

SIGNED by Matthew Alan **GREGORY**



.....

Date 3rd December 2015

in the presence of:



.....

JAMES SCOBLE
BAWSTON
CAMBRIDGE

SIGNED by Barrie WILKINSON


.....

Date.....

in the presence of:

.....

SIGNED by ISOMERASE:

.....

Date..... 13/12/2015.....

Name: M. Green.....

Capacity: CEO.....

CONFIRMATORY ASSIGNMENT

WHEREAS WE Steven James MOSS a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom, **Matthew Alan GREGORY** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom and **Barrie WILKINSON** a British citizen of Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom (hereinafter called the "**Inventors**") have invented or discovered "**NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION**" (hereinafter called the "**Invention**") for which a PCT patent application was filed at the European Patent Office as Receiving Office under number PCT/GB2014/052094 on 9th July 2014 claiming priority to a patent application filed at the Intellectual Property Office in the United Kingdom under number 1312318.7 on 9th July 2013 (hereinafter called the "**Applications**");

WHEREAS Steven James MOSS, Matthew Alan GREGORY and Barrie WILKINSON were employed at the time of making of the **Invention** by **Isomerase Therapeutics Ltd.** whose registered address is Science Village, Chesterford Research Park, Cambridge CB10 1XL, United Kingdom (English company number 08335008, hereinafter called "**ISOMERASE**") and whereas the invention was made in the course of employment under circumstances whereby an invention may reasonably be expected to result and all rights in and to the invention are assigned to **ISOMERASE** by operation of law, specifically s39 of the Patents Act 1977, and moreover by virtue of a specific assignment clause in their contracts of employment;

WHEREAS the Inventors and ISOMERASE have authorised and requested the filing of the **Applications**;

NOW, THEREFORE, to all whom it may concern be it known that for consideration of the sum of £1 (one pound sterling) or other valuable consideration, the sufficiency of which is hereby acknowledged, we the **Inventors** hereby confirm the ownership by **ISOMERASE** of the **Invention** and the **Applications** and hereby assign and transfer to **ISOMERASE** all ownership right, title and interest in and to the **Invention** and the **Applications** and to any priority rights for all territories of the world in respect of the **Invention** and the **Applications** and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension, or re-issue thereof, or Supplementary Protection Certificate based

thereon, and we the **Inventors** hereby authorise and request any patent arising therefrom in any territory of the world be issued to **ISOMERASE**;

AND we the **Inventors** for ourselves and our respective executors and legal representatives hereby agree to provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **ISOMERASE** its successors and assigns, the whole right, title and interest in and to the **Invention** and the **Applications**.

IN WITNESS whereof and with effect from 9th July 2013 the **Inventors** and **ISOMERASE** through its authorised official have hereunto set their respective hands:

SIGNED by **Steven James MOSS**

..... Date.....

in the presence of:

.....


SIGNED by **Matthew Alan GREGORY**

..... Date.....

in the presence of:

.....

SIGNED by Barrie WILKINSON




Date 10/12/2015

in the presence of:

Tom Scott

THOMAS SCOTT 10/12/15

SIGNED by ISOMERASE:



Date 18th December 2015

Name: M. Gregory

Capacity: CEO

CONFIRMATORY ASSIGNMENT

5/10/15
04 Dec 2015
6 Cooper Road

WHEREAS I Steven KENDREW a British citizen of ~~Riverside 3, Granta Park,~~ Cambridge, ~~CB21 6AD,~~ United Kingdom (hereinafter called the "Inventor") have invented or discovered some or all of "**NOVEL COMPOUNDS AND METHODS FOR THEIR PRODUCTION**" (hereinafter called the "Invention") for which a PCT patent application was filed at the European Patent Office as Receiving Office under number PCT/GB2014/052094 on 9th July 2014 claiming priority to a patent application filed at the Intellectual Property Office in the United Kingdom under number 1312318.7 on 9th July 2013 (hereinafter called the "**Applications**");

WHEREAS Steven KENDREW was employed at the time of making of the **Invention** by **Biotica Technology Ltd.** whose registered address is Riverside 3, Granta Park, Cambridge, CB21 6AD, UK (English company number 03243295, hereinafter called "**BIOTICA**") and whereas the invention was made in the course of employment under circumstances whereby an invention may reasonably be expected to result and all rights in and to the invention are assigned to **BIOTICA** by operation of law, specifically s39 of the Patents Act 1977, and moreover by virtue of a specific assignment clause in his contract of employment;

WHEREAS Isomerase Technology Ltd. whose registered address is Suite 9, Science Village, Chesterford Research Park, Cambridge, CB10 1XL, United Kingdom (English company number 08335008, hereinafter called "**ISOMERASE**") has acquired all rights to this invention from **BIOTICA** by virtue of an agreement dated 15th March 2013;

WHEREAS the Inventor and ISOMERASE have authorised and requested the filing of the **Applications**;


NOW, THEREFORE, to all whom it may concern be it known that for consideration of the sum of £1 (one pound sterling) or other valuable consideration, the sufficiency of which is hereby acknowledged, I the **Inventor** hereby confirm the ownership by **ISOMERASE** of the **Invention** and the **Applications** and hereby assign and transfer to **ISOMERASE** all ownership right, title and interest in and to the **Invention** and the **Applications** and to any priority rights for all territories of the world in respect of the **Invention** and the **Applications** and in and to any divisional application, continuation or continuation in part application thereof, and in and to any extension, or re-issue

thereof, or Supplementary Protection Certificate based thereon, and I the **Inventor** hereby authorise and request any patent arising therefrom in any territory of the world be issued to **ISOMERASE**;

AND I the **Inventor** for myself and my executors and legal representatives hereby agree to provide information and make, execute and deliver any and all other instruments in writing, and any and all further acts, applications, papers, affidavits, assignments and other documents which may be possible and are necessary or desirable to more effectually secure to and vest in **ISOMERASE** its successors and assigns, the whole right, title and interest in and to the **Invention** and the **Applications**.


IN WITNESS whereof and with effect from 9th July 2013 the **Inventor** and **ISOMERASE** through its authorised official have hereunto set their respective hands:

SIGNED by Steven KENDREW



.....

Date... 09 - Dec 2015

in the presence of:


.....

SIGNED by ISOMERASE:


.....

Date 08/12/2015
.....

Name: M. GREGORY
.....

Capacity: CEO
.....

